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DC is an inherited bonemarrow failure syndrome (BMF)with
a high predisposition to cancer development. The HSCT is the
only curative treatment for BMF associated but imposes
signiﬁcant toxicity. We reported the outcome of 12 pts who
underwent bone marrow transplantation for DC between
July 1993 and May 2013 in a single institution. The median
age at transplantationwas 16,5 years (range 3 to 27). Two pts
had the non classical forms of disease (Revesz syndrome and
severe aplastic anemia with evidence of short telomeres).
Five pts received bone marrow from their HLA matched
siblings and were conditioned with Cyclophosphamide (CY)
200mg/Kg. Seven pts were transplanted from unrelated do-
nors (URD): 6 BM (match 10/10: 4pts and 9/10: 2pts) and 1
CB (5/6). Conditioning Regimen for the URD BMT was CY30-
60mg/Kg + Fludarabine125mg/m2 + rabbitATG5mg/Kg and
CB Busulfan12mg/Kg + Fludarabine125mg/m2 + rATG5mg/
Kg. Graft versus host disease (GVHD) prophylaxis: metho-
trexate and cyclosporine for all patients, except for the one
who received CBU. Median of TNC: BM: 3.97 x 108/Kg. CBU:
6.5 x107/Kg. All pts survived more than 28 days and were
available for engraftment. All but one pt had stable hema-
tological engraftment. Chimerismwas complete in 7 patients
and mixed in the other 5 patients. Mucositis was the only
toxicity observed (grade II in 5 pts and grade III in 2 pts).
GVHD was observed only among unrelated transplants. Two
pts developed grade II acute GVHD and both progressed to
chronic GVHD (limited). The probability of survival in 2 year
was 50%. Two deaths were related to the procedure (SOS and
adenovirus sepsis). Four pts died between 1 and 10 years
after transplant because of progression of underlying dis-
ease. Six patients (4 recipients of an URD) are alive between 6
months and 11 years after transplant with a median follow
up of 1.6 years.
Conclusions: Regimen related toxicity was very low and an
appropriate engraftment was achieved. Late mortality was
consequent to the progression of underlying disease. Long
term follow up is essential in order to detect late complica-
tions related to the transplant procedure or the underlying
disease.375
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of Wisconsin, Milwaukee, WIHistiocytic disorders are rare but often fatal illnesses. Within
these, familial and secondary hemophagocytic lymphohis-
tiocytosic disorders (HLH) are primarily diagnosed in child-
hood, and there have been few large analyses of outcomes in
adults with HLH. The widely-accepted HLH-94 treatment
regimen consisting of dexamethasone, etoposide and cyclo-
sporine therapy followed by allogeneic stem cell trans-
plantation (SCT) has been employed primarily in children. In
the largest series to date of 113 children under 15 years of
age, a 3 year survival rate of 55% overall and 62% for those
receiving allogeneic SCT was seen (Henter. Blood 2002;
100:2367-2372). In light of the highly proinﬂammatory
cytokine environment that characterizes HLH, alemtuzumab
for profound lymphocyte depletion in concert with condi-
tioning for pediatric SCT is becoming increasingly common,
with an impact on rates of acute GvHD andmixed chimerism
reported. (Marsh. Blood 2010;116:5824-5831; Marsh. Pediatr
Blood Cancer 2013;60:101-109). To assess current practices
and outcomes in adults, we performed a retrospective re-
view using the CIBMTR database of all subjects over 18 years
of age receiving allogeneic SCT for histiocytic conditions
between 2001 and 2012.
Results: 47 subjects were identiﬁed, 16 of whom were
transplanted in 2011 or 2012. Median age was 25 (18-67).
Underlying diagnoses were familial HLH (47%), secondary
HLH (32%), malignant histiocytosis (15%), and histiocytic
disorders not otherwise speciﬁed (6%). 31 subjects (66%)
received transplants from unrelated donors. 26 subjects
(55%) received PBSCs. The remaining subjects received bone
marrow, except for one who received umbilical cord blood.
26 subjects (56%) received myeloablative conditioning, pri-
marily cytoxan-TBI-based or cytoxan and busulfan. 21 sub-
jects underwent reduced-intensity or non-myeloablative
conditioning with ﬂudarabine-based regimens. 18 subjects
(38%) underwent conditioning in combination with alem-
tuzumab. Kaplan-Meier survival rate estimates for the entire
cohort were 93% at 100 days (95% CI, 71-93), 60% at one year
(95% CI, 45-75) and 57% at 2 years (95% CI, 40-72).
Conclusions: Adults with histiocytic disorders, primarily
HLH, have survival rates after allogeneic SCT similar to those
seen in the pediatric literature. Inclusion of alemtuzumab
prior to or in concert with conditioning is common in adults.
Allogeneic SCT regimens for HLHmerit prospective studies in
adults as well as children. We encourage participation in the
BMT-CTN 1204 study, a phase II study of reduced-Intensity
conditioning for children and adults with hemophagocytic
syndromes or selected primary immune deﬁciencies pre-
ceded by alemtuzumab therapy.376
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Complications of allogeneic stem cell transplant, such as
infection, relapse and GvHD, are linked to failure of balanced
immune reconstitution. Early quantiﬁcation of immunologic
